In the BALLI-01 Phase 1 trial (NCT04150497), five adult patients at a median age of 24 years (22–52 years) with R/R B-ALL received UCAR-T22 (allogeneic anti-CD22/41BB construct). Here, CD22 is linked to acute lymphoblastic leukemia.